Can reach 0.70 today

It will rebound tomorrow.

It has risen a lot before and now it is normal to adjust some.

It is not a problem that this counter will go to RM20 next year.

Large households will enter at any time.

There is no need to worry about the rebound sooner or later.

Collect while low.

Performance time is coming.

It may close higher this afternoon.

Bursa Malaysia Latest Dividend News

ENTITLEMENT NEWS
COMPANY NAME KARYON INDUSTRIES BERHAD
STOCK CODE/SHORT NAME KARYON/0054
ANNOUNCEMENT DATE 01 Oct 2020
SUBJECT Second Interim Dividend .7 cent
CONTENT
EX-DATE 14 Oct 2020 ENT. IN % 0.00
ENTITLEMENT DATE 15 Oct 2020 ENT. IN CENT 0.7000
PAYMENT DATE 30 Oct 2020 ENT. NUMERATOR -
TRANSFER DATE 15 Oct 2020 ENT. DENUMERATOR -

Be careful with the suite.

The shark is here again.

5073 NAIM NAIM HOLDINGS BHD
General Meetings: Outcome of Meeting

52047Indication: Notice of MeetingIndication: Outcome of MeetingDate of Meeting: 06/10/2020Time of Meeting: 10:00 AMVenue: Employee Lounge, Naim Holdings Berhad,10th Floor, Wisma Naim,2 1/2 Mile,Rock Road,93200 Kuching, Sarawak,MalaysiaOutcome of Meeting: The Board of Directors of Naim Holdings Berhad is pleasedto announce that the ordinary resolution as set down in the Notice ofExtraordinary General Meeting ("EGM") dated 21 September 2020 has been approvedby the shareholders at the EGM held earlier today. The ordinary resolutionwas voted by poll and the results of the poll were validated by ScrutineerSolutions Sdn. Bhd., the independent scrutineer appointed by the Company.Remark:You are advised to read the entire contents of the announcement or attachment.To read the entire contents of the announcement or attachment, please accessthe Bursa website at http://www.bursamalaysia.com


06/10/2020 12:32 PM

Don't worry about it rising.

Noon will be the show time.

Duopharma stock rises as EPF increases stake
TheEdge Mon, Oct 05, 2020 10:45am - 51 minutes ago


KUALA LUMPUR (Oct 5): Duopharma Biotech stock price has seen a steady rise since July amid vaccine optimism and it is expected to continue its upward momentum as the Employees Provident Fund (EPF) has increased its holdings.

An analyst said retail investors usually would mirror the movement of institutional investors which would be on a “buy low sell high” trend.

“The two top pharmaceutical companies in Malaysia, namely Pharmaniaga, which is owned by the Armed Forces Fund Board (LTAT), and Duopharma would be the biggest gainers once the COVID-19 vaccine is available.

“Hence, the prospects for ‘buy’ is maintained for the long run,” she said.

In terms of stake, Duopharma’s majority shareholder Bumiputera Investment Foundation holds 46.5 per cent, EPF (7.82 per cent) and Permodalan Nasional Bhd (4.94 per cent).

As at 10.26pm, Duopharma stock rose five sen to RM3.38 with 1.94 million shares traded.

I believe it will limit up today.

It would be great if it rose like G3.

What price is the limit up? .

will limit up again today.

Today it will be above 0.3.

Kanger International Bhd has inked an agreement with Sinopharm Group Hunan Changde Medical Co Ltd (SGHC) to distribute a Covid-19 vaccine and medical equipment products in Malaysia. Kanger will be SGHC’s product distributor in Malaysia with priority right of purchase of the products made by the Sinopharm unit. The agreement is effective until Sept 24, 2023.

It's almost coming.

limit down

limit down is coming.

0.20 sen per share

They really write 0.20 at bursa announcement. Will they compensate if mistake

Not many people have found this counter yet.

This is also a good counter.

DPIH - Notice of Book Closure
DPIH - Notice of Book Closure
ILC-25092020-00001
First Interim Dividend Single Tier dividend of 0.20 sen per share for the
financial year ending 31 May 2021. Kindly be advised of the following : 1)
The above Company's securities will be traded and quoted "Ex - Dividend? as
from: 9 Oct 2020 2) The last date of lodgment : 12 Oct 2020 3) Date Payable :
30 Oct 2020
MANAGER, REF. DATA MANAGEMENT
You are advised to read the entire contents of the announcement or attachment.
To read the entire contents of the announcement or attachment, please access
the Bursa website at http://www.bursamalaysia.com


25/09/2020 07:45 AM


Ref Code: 202009255100007
25/09/2020 9:02 AM

DPIH Quarter Report History
Date Financial
Year Quarter Revenue
(RM,000) PBT (RM,000) Net Profit
(RM,000) EPS (Cent) Div
(Cent) NTA
(RM) QoQ
(%) YoY
(%)
24 Sep 20 31 May 21 Q1 Aug 20 15,560 4,396 3,279 0.67 0.20 0.160 Malaysia Stock - KLSE Quarter Report History 350% Malaysia Stock - KLSE Quarter Report History 100%
25/09/2020 9:06 AM

This counter will fall to 0.50.

https://www.sinchew.com.my/content/content_2347847.html?fbclid=IwAR09wsvFgbRhIlCpczdxq7HPjORIPYEzzeM7oSOuOxiNBUvHebTtwACaXKw

Give up this counter and buy this

7247 SCGM SCGM BHD
Final Dividend

Entitlement Details:
Final single tier dividend of 0.35 sen per ordinary share in respect of the
financial year ended 30 April 2020.


Entitlement Type: Final Dividend
Entitlement Date and Time: 13/10/2020 05:00 PM
Year Ending/Period Ending/Ended Date: 30/04/2020
EX Date: 12/10/2020
To SCANS Date:
Payment Date: 28/10/2020
Interest Payment Period:
Rights Issue Price: 0.000
Trading of Rights Start On:
Trading of Rights End On:
Stock Par Value:

Share transfer book & register of members will be closed from 13/10/2020 to 13/10/2020 (both dates inclusive) for the purpose of determining the entitlements

A Depositor shall qualify for the entitlement in respect of:
- Securities transferred into the Depositor's Securities Account before 13/10/2020 04:30 PM in respect of ordinary transfers.
- Securities transferred into the Depositor's Securities Account before in respect of express transfers.
- Securities deposited into the Depositor's Securities Account before in respect of securities exempted from mandatory deposit.
- Securities not withdrawn from the Depositor's Securities Account as at .
- Securities bought on BMSB on a cum entitlement basis according to the Rules of the BMSB.

Registrar's Name and Contact:
MEGA CORPORATE SERVICES SDN BHD,Level 15-2, Bangunan Faber Imperial
Court,Jalan Sultan Ismail,50250,Kuala Lumpur,Wilayah
Persekutuan,MalaysiaTel:0326924271Fax:0327325388


Remarks:
Arising from the migration to the no par value regime under the Companies
Act 2016, par value is no longer relevant.The proposed final dividend will be
subject to the shareholders' approval at the forthcoming annual general meeting
of the Company.
You are advised to read the entire contents of the announcement or attachment.
To read the entire contents of the announcement or attachment, please access
the Bursa website at http://www.bursamalaysia.com


Submitted By:



24/09/2020 12:41 PM


Ref Code: 202009243200038

limit up is coming.

There is no limit up today and we have to wait for tomorrow.

Solution Group subsidiary signs agreement with CanSino to distribute novel coronavirus vaccine
TheEdge Wed, Sep 23, 2020 03:38pm - 13 minutes ago


KUALA LUMPUR (Sept 23): Solution Group Bhd's subsidiary Solution Biologics Sdn Bhd and China-based CanSino Biologics Inc today signed a registration, manufacturing and commercialisation agreement, which will enable Solution Biologics to market and distribute in Malaysia the novel coronavirus vaccine developed by CanSino.

In a statement to Bursa Malaysia today, Solution Group said Solution Biologics will register with Malaysia's National Pharmaceutical Regulatory Agency to apply for the market authorisation certificate.

Solution Group said Solution Biologics "will establish a state-of-the-art fill and finish facility" to host a technology transfer for the filling, finishing and final quality control of CanSino's recombinant novel coronavirus vaccine.

The facility will be established at Solution Biologics' current premises at PT13796, Jalan Tekno Usahawan 2, Technology Park Malaysia in Bukit Jalil here.

"CanSino will collaborate with Solution Biologics in obtaining the necessary approvals [including the marketing authorisation] for the purposes of the registration and commercialisation of the product in Malaysia.

"Upon the product's registration, CanSino will be partnering with Solution Biologics in supplying to Solution Biologics of bulk product for further manufacturing (fill and finish) of the finished product, its final quality control release and its commercialisation by Solution Biologics in Malaysia," Solution Group said.

"Upon the successful implementation of the terms, interests and the intention of the parties as set out in the agreement, Solution Group expects the collaboration will contribute positively to its earnings in the future," Solution Group said.

At 3.14pm today, Solution Group's share price rose four sen or 5.8% to 73 sen for a market capitalisation of RM223.51 million. The stock saw some 107 million shares traded.

Solution Group subsidiary signs agreement with CanSino to distribute novel coronavirus vaccine
TheEdge Wed, Sep 23, 2020 03:38pm - 13 minutes ago


KUALA LUMPUR (Sept 23): Solution Group Bhd's subsidiary Solution Biologics Sdn Bhd and China-based CanSino Biologics Inc today signed a registration, manufacturing and commercialisation agreement, which will enable Solution Biologics to market and distribute in Malaysia the novel coronavirus vaccine developed by CanSino.

In a statement to Bursa Malaysia today, Solution Group said Solution Biologics will register with Malaysia's National Pharmaceutical Regulatory Agency to apply for the market authorisation certificate.

Solution Group said Solution Biologics "will establish a state-of-the-art fill and finish facility" to host a technology transfer for the filling, finishing and final quality control of CanSino's recombinant novel coronavirus vaccine.

The facility will be established at Solution Biologics' current premises at PT13796, Jalan Tekno Usahawan 2, Technology Park Malaysia in Bukit Jalil here.

"CanSino will collaborate with Solution Biologics in obtaining the necessary approvals [including the marketing authorisation] for the purposes of the registration and commercialisation of the product in Malaysia.

"Upon the product's registration, CanSino will be partnering with Solution Biologics in supplying to Solution Biologics of bulk product for further manufacturing (fill and finish) of the finished product, its final quality control release and its commercialisation by Solution Biologics in Malaysia," Solution Group said.

"Upon the successful implementation of the terms, interests and the intention of the parties as set out in the agreement, Solution Group expects the collaboration will contribute positively to its earnings in the future," Solution Group said.

At 3.14pm today, Solution Group's share price rose four sen or 5.8% to 73 sen for a market capitalisation of RM223.51 million. The stock saw some 107 million shares traded.

The price has been increasing.

You can read it (Sin Chew Daily Finance).

Be careful, Itricked you into coming in and then falling again.

It is clear that at present, the company does not have any glove production lines.

Fell to the minimum to buy and wait for a rebound.

He followed HLT up and down.

OTHERS LKL INTERNATIONAL BERHAD ("LKL INTERNATIONAL" OR THE "COMPANY") - SALES CONTRACT AWARDED TO LKL ADVANCE METALTECH SDN. BHD. ("LKLAM"), A WHOLLY-OWNED SUBSIDIARY OF LKL INTERNATIONAL, FOR THE SUPPLY OF NITRILE GLOVES
LKL INTERNATIONAL BERHAD

https://www.klsescreener.com/v2/announcements/view/3228681

LKL: Reveals details of firm granting glove supply contract. LKL International has finally revealed the identity of the Chinese company that granted it the RM78.5m nitrile glove supply contract. “Further to the company's announcements made on Sept 2 and Sept 7, 2020 in relation to the sales contract awarded to LKLAM (LKL Advance Metaltech SB) for the supply of nitrile gloves, the board of directors of LKL International wishes to announce that the name of the customer is Weihai Textile Group Import and Export Co, Ltd.” (The Edge)

I believe the good news is coming.

Be careful that WA falls first.

Buying HLT, MMAG, LKL is more profitable.

Compared with HLT and MMAG, LKL is a bit worse.

Maybe it will fall tomorrow.

https://www.klsescreener.com/v2/news/view/728125/duopharma-biotech-to-produce-second-oncology-medicine
Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

KUALA LUMPUR: Pharmaceutical firm Duopharma Biotech Bhd, through wholly-owned subsidiary Duopharma HAPI Sdn Bhd, will soon manufacture its second oncology drug at its first-in-Malaysia highly potent active pharmaceutical ingredient (HAPI) Plant in Shah Alam to help address the paucity of affordable alternatives to treat cancer.

Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

The HAPI plant is equipped to produce a wide portfolio of cancer medicines to help to treat, among others, breast cancer, lung cancer, colorectal cancer, cervical cancer, and blood cancer, making it the first cancer medicine manufacturing facility in Malaysia.

Duopharma Biotech group is embracing innovation and technology to serve patients who need specific and targeted therapies that can be produced by our new state-of-the-art HAPI Plant, he said in a statement to Bernama today.

The facility is also fully capable of producing medicines to treat hormonal imbalance and highly potent medicines for cardiovascular, central nervous system and musculoskeletal diseases. In the first quarter of this year, Duopharma Biotech successfully manufactured and commercialised its first product (letrozole), which is prescribed for breast cancer treatment.

Leonard Ariff revealed that the HAPI plant’s next product would be the first locally manufactured drug to treat chronic myeloid leukemia for both adults and children.

"The medicine which will be produced locally is targeted to be commercialised in due course,” he said.

This medicine produced at the HAPI plant, which is available at an affordable price, will enable patients especially in the low and middle income categories to have access to the treatment.

"Affordability and access issues are especially prevalent amongst the financially challenged and there is evidence that out-of-pocket costs for such prescription drugs to treat chronic diseases not only impose a financial burden but result in reduction in medication adherence leading to worsening health outcomes.

"Our objective in establishing the HAPI plant in Malaysia is premised on a mission to offer medication to address the lack of alternatives while delivering equitable and affordable access to prescription medications. The plant will also provide some level of self-sufficiency to the country in terms of the specific oncology medications,” he said.

The HAPI facility is a Good Manufacturing Practice certified plant by the Malaysian National Pharmaceutical Regulatory Agency (NPRA). This ensures that production and quality control consistently meet the highest standards.

Duopharma Biotech is also currently engaging with pharmaceutical companies across the globe to bring high-end technologies and allowing for technology transfer which enables it to locally manufacture high-value drugs.

This is expected to further strengthen the company’s position as the leading pharmaceutical player in Malaysia, and help it achieve its target of being a leading pharmaceutical company in Southeast Asia.

"We are widening our product portfolio by offering not just oncology medicines but also psychotropic drugs, which is an emerging market in Malaysia.

"Duopharma Biotech has already established a strong presence in the anti-psychotic sector and is collaborating with our partners to bring in more locally manufactured psychotropic drugs into our pipelines due to their huge market potential,” he added. - Bernama